Stock comparison
Abbott Laboratories
Royalty Pharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ABT
Abbott Laboratories
Market cap
$152.25B
Sector
Healthcare
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
Overall winner
Royalty Pharma RPRX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ABT | RPRX | Winner |
|---|---|---|---|
| Warren Buffett | 61C | 66C | RPRX |
| Benjamin Graham | 69B | 84A | RPRX |
| Philip Fisher | 46D | 65C | RPRX |
| Peter Lynch | 24F | 60C | RPRX |
| Joel Greenblatt | 42D | 40D | ABT |
| Charlie Munger | 57C | 68D | RPRX |
| Terry Smith | 54D | 58D | RPRX |
Side-by-side metrics
| Metric | ABT | RPRX |
|---|---|---|
| Market cap | $152.25B | $23.44B |
| P/E (TTM) | 23.5x | 27.6x |
| EV/EBIT | 21.7x | 19.9x |
| ROIC (TTM) | 6.56% | 8.43% |
| Gross margin | 56.38% | 99.95% |
| Net margin | 13.91% | 33.91% |
| Revenue CAGR 5y | 0.72% | 0.96% |
| EPS CAGR 5y | -1.48% | 11.83% |
| Debt / Equity | 0.7x | 1.3x |
| Dividend yield | 2.89% | 1.72% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ABT leads on
- Market cap$152.25Bvs $23.44B+85%
- Debt / Equity0.7xvs 1.3x+50%
- Dividend yield2.89%vs 1.72%+40%
- P/E (TTM)23.5xvs 27.6x+15%
RPRX leads on
- EPS CAGR 5y11.83%vs -1.48%+113%
- Net margin33.91%vs 13.91%+59%
- Gross margin99.95%vs 56.38%+44%
- Revenue CAGR 5y0.96%vs 0.72%+25%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.